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Unlocking	the	potential	of	anti-CD33	therapy	in	adult	and	childhood	Acute	
Myeloid	Leukaemia	(AML)	
	Acute	 Myeloid	 Leukaemia	 (AML)	 develops	 when	 there	 is	 a	 block	 in	 differentiation	 and	uncontrolled	 proliferation	 of	 myeloid	 precursors,	 resulting	 in	 bone	 marrow	 failure.	 AML	 is	 a	heterogeneous	 disease	 clinically,	 morphologically,	 and	 genetically,	 and	 biological	 differences	between	adult	and	childhood	AML	have	been	identified.	AML	comprises	15-20%	of	all	children	less	than	fifteen	years	diagnosed	with	acute	leukaemia.	Relapse	occurs	in	up	to	40%	of	children	with	AML	and	is	the	commonest	cause	of	death.1,2	Relapse	arises	from	leukaemic	stem	cells	(LSCs)	that	persist	after	conventional	chemotherapy.	The	treatment	of	AML	is	challenging	and	new	strategies	to	 target	LSCs	are	 required.	The	cell	 surface	marker	CD33	has	been	 identified	as	a	 therapeutic	target,	and	novel	anti-CD33	immunotherapies	are	promising	new	agents	in	the	treatment	of	AML.	This	review	will	summarise	recent	developments	emphasising	the	genetic	differences	in	adult	and	childhood	AML,	while	highlighting	the	rationale	for	CD33	as	a	target	for	therapy,	in	all	age	groups.		
Differences	in	genetic	profiles	in	adult	compared	to	childhood	AML		Adult	 and	 childhood	 AML	 differ	 significantly	 in	 the	 incidence	 and	 pattern	 of	 cytogenetic	 and	molecular	abnormalities,	suggesting	a	different	pathogenesis	according	to	age.3–5	Childhood	AML,	in	comparison	to	adult	AML,	is	characterised	by	a	higher	frequency	of	cytogenetic	abnormalities	creating	fusion	genes	(e.g.	RUNX1-RUNX1T1,	KMT2A-rearrangements	and	NUP98-NSD1),	specific	chromosomal	 translocations	e.g.	 t(1;22)(p13;q13)/RBM15-MKL1,	 t(7;12)(q36;p13)/ETV6-MNX1	and	 t(11;12)(p15;p13)/NUP98-KDM5A)	 that	occur	almost	exclusively	 in	 childhood	and	a	 lower	frequency	of	genetic	mutations	(e.g.	DNMT3A	and	IDH1/2).	6	(Table	1)	Childhood	AML	also	differs	from	 adult	 AML	 in	 the	 incidence	 of	 AML	 arising	 from	 an	 underlying	 myeloproliferative	 or	myelodysplastic	condition.	In	children,	the	vast	majority	of	patients	present	with	de	novo	AML.	In	adults,	 there	 is	 a	 higher	 incidence	 of	 patients	 with	 an	 antecedent	 myeloid	 disorder	 e.g.	myelodysplastic	 syndromes	 (MDS)	and	myeloproliferative	neoplasm	(MPN),	 and	who	meet	 the	World	Health	Organisation	(WHO)	classification	for	AML	with	myelodysplasia-related	changes.7	Studies	reviewing	predominately	adult	populations,	have	found	this	group	to	account	for	24-35%	of	 all	 AML	 and	 it	 is	 associated	 with	 poorer	 outcome,	 increasing	 age,	 poor	 risk	 cytogenetic	abnormalities	and	specific	gene	mutations.8	For	example,	AML	evolving	from	MDS	has	mutations	involving	splicing	factors	(SRSF2,	SF3B1,	UZAF1	and	ZRSR2),	epigenetic	regulators	(ASXL1,	EZH2,	BCOR)	and	members	of	the	cohesion	complex	(STAG2).7		In	adult	AML,	40%	of	patients	have	a	normal	karyotype	with	increasing	numbers	of	recognized	driver	 mutations	 that	 allow	 patients	 to	 be	 categorised	 into	 prognostic	 groups,	 providing	 new	potential	therapeutic	targets.	Papemmanuil	et	al,	have	proposed	a	new	genomic	classification	of	adult	 AML.	 In	 addition	 to	 the	 existing	 WHO	 criteria,	 they	 suggest	 three	 additional	 categories	identifying	 patients	with	mutations	 in	 chromatin	 remodelling	 and	RNA	 splicing	 pathways	 (e.g.	RUNX1,	MLL,	ASXL1,	STAG2,	DNMT3A,	TET2),	TP53	mutations	and	chromosomal	aneuploidy,	and	AML	 with	 IDH2	 mutations.5	 In	 addition,	 Ng	 et	 al,	 have	 identified	 a	 selection	 of	 prognostic	biomarkers	(LSC17	score)	from	genes	differentially	expressed	in	functional	LSCs	compared	to	the	LSC	negative	AML	fraction	after	correlation	with	clinical	outcomes	in	adults.9	The	17	genes	include	those	associated	with	AML	e.g.	DNMT3B,	SOCS2	and	CD34,	and	additionally	genes	whose	role	in	haematopoiesis	is	less	clear.	This	score	was	shown	to	be	able	to	identify	high-risk	patients	with	poor	survival	outcomes	and	response	to	treatments,	including	anti-CD33	antibody-drug	conjugate	(ADC)	Gemtuzumab	Ozogamicin	(GO),	across	a	spectrum	of	AML	genotypes.	They	summarised	that	a	 high	 LSC17	 score	 in	 patients	 reflected	 stemness	 properties	 that	 allow	 the	 LSCs	 to	 resist	treatment,	identifying	patients	as	poor	risk.	These	recent	developments	in	genomic	classification	are	helpful	in	progressing	our	knowledge,	treatment	plans	and	risk	stratification	for	adult	patients.			Childhood	AML	has	been	shown	to	have	a	different	genetic	landscape	and	the	same	classification	systems	may	 not	 be	 applicable	 to	 paediatric	 patients.	 Only	 20%	 of	 paediatric	 patients	 have	 a	normal	 karyotype	 and	 the	 number	 of	 somatic	 mutations	 is	 lower	 than	 in	 adult	 AML	 (5	 per	paediatric	sample	versus	10-13	per	adult	sample).4	Shiba	et	al	recently	published	whole	exome	sequencing	and	targeted	sequencing	of	paediatric	patients.	In	their	cohort,	they	identified	three	major	categories	of	recurrently	mutated	genes	in	addition	to	CEBPA	(11%),	WT1	(7.8%)	and	NPM1	
(3.4%);	 these	 were	 the	 cohesion	 complex	 (RAD21,	 SMC3	 and	 STAG2),	 epigenetic	 regulators	(ASXL2,	 BCOR/BCORL1,	 EZH2),	 and	 signalling	 molecules	 (NRAS,	 KRAS,	 KIT,	 MPL,	 FLT3-ITD).	ASXL1/2	mutations	were	seen	in	8.8%	of	the	cohort	and	61%	had	co-existing	t(8;21)(q22;q22).	In	contrast	to	adult	patients,	where	this	mutation	is	associated	with	poor	outcomes,	the	additional	ASXL1/2	mutation	in	children	in	this	cohort	did	not	result	in	a	change	of	the	favourable	overall	survival	associated	with	t(8;21)	alone.4	No	mutations	where	detected	in	the	epigenetic	modifiers,	IDH1	 or	 DNMT3A	 and	 mutations	 were	 rarely	 seen	 in	 IDH2,	 TET	 and	 BRAF;	 all	 of	 which	 are	frequently	mutated	in	the	adult	population.	This	illustrates	some	of	the	major	differences	between	the	 genetic	 abnormalities	 in	 childhood	 and	 adult	 AML,	 with	 different	 frequencies	 of	 common	mutations	and	unique	mutations	within	each	group.			Another	potential	difference	in	the	pathogenesis	of	childhood	and	adult	AML	is	the	developmental	properties	of	the	cell	of	origin.	There	is	evidence	that	the	age	and	microenvironment	of	the	cell	of	origin	plays	a	significant	role	in	the	initiation	and	phenotype	of	a	resultant	leukaemia	following	genetic	hits.3,10,11	The	intrinsic	and	extrinsic	properties	of	haematopoietic	stem	cells	(HSCs)	change	in	 the	 normal	 ageing	 process.	 For	 example,	 fetal	 liver	HSCs	 have	 enhanced	 expression	 of	 self-renewal	and	cell	cycling	genes	compared	to	adult	HSCs.	Adult	normal	HSCs	are	quiescent	cells	that	show	different	gene	expression	profiles	with	increasing	age.	For	example,	there	is	upregulation	of	genes	involved	in	myeloid	lineage	determination,	DNA	repair	and	cell	death	in	HSCs	from	adults	over	65	years	compared	to	younger	adult	HSCs.3	In	the	fetus,	HSCs	are	first	identified	at	the	late	stages	of	mid-gestation	within	the	aorta-gonad-mesonephros	(AGM)	region	and	then	move	to	the	fetal	liver	and	spleen	before	finally	settling	within	the	bone	marrow	niche	just	before	birth.12	The	normal	fetal	HSCs	therefore	transition	through	a	different	microenvironment	and	are	exposed	to	different	extrinsic	factors	that	may	influence	the	response	of	the	cell	of	origin	to	a	driver	mutation.	The	cell	of	origin	or	leukaemia	initiating	cell	in	AML	does	not	always	arise	from	the	pluripotent	HSCs,	and	it	is	important	to	consider	the	inherent	properties	and	age	related	changes	of	normal	haematopoiesis	when	considering	leukaemogenesis.			Despite	the	differences	discussed	between	adult	and	childhood	AML,	the	main	genetic	driver	often	dictates	 the	 phenotype	 and	 prognosis	 of	 the	 disease,	 regardless	 of	 the	 age	 of	 the	 patient.	 For	example,	the	cryptic	NUP98-NSD1	translocation	is	found	more	frequently	in	children	than	adults.	However,	patients	of	all	ages	with	this	translocation	present	with	higher	white	blood	cell	counts,	have	a	specific	gene	expression	signature	and	very	frequently	also	harbour	FLT3-ITD	and	WT1	mutations	compared	to	NUP98-NSD1	negative	cases.13	The	presence	of	NUP98-NSD1	was	also	an	independent	predictor	for	poor	prognosis,	with	4	year	event	free	survival	being	less	than	10%	for	both	childhood	and	adult	AML.13			The	differences	in	the	pathogenesis	of	adult	and	childhood	AML	is	important	clinically	as	to	date,	treatment	of	childhood	AML	is	largely	extrapolated	from	adult	regimes.	In	the	future,	as	we	aim	for	a	precision	medicine	approach,	the	differences	in	adult	and	childhood	AML	need	to	be	considered	to	allow	appropriate	prognostic	classifications	and	effective	treatments	to	be	allocated.			Table	 1.	 Incidence	 of	 genetic	 abnormalities	 with	 age	 and	 associated	 CD33	 expression	 and	immunophenotype.	14–41		
The	role	of	the	LSC	in	AML		Over	the	past	two	decades,	development	of	laboratory	techniques	has	allowed	the	identification	and	characterisation	of	LSCs,	primarily	in	adult	AML.	LSCs	are	a	small	population	of	cells	that	are	capable	of	self-renewal	as	well	as	producing	the	‘bulk’	AML	blasts.	It	is	thought	that	like	normal	haematopoiesis,	there	is	an	organisational	hierarchy	in	AML,	with	LSCs	at	the	top	producing	more	differentiated	 leukaemic	 progeny.42,43	 LSCs	 have	 similar	 properties	 to	 normal	 HSCs,	 including	quiescence,	self-renewal	capabilities	and	engraftment	potential.	LSCs	are	more	complex	however,	with	aberrant	expression	of	cell	surface	markers,	for	example	CD33,	CLL-3,	CD123	and	CD45RA.44–47	This	may	be	explained	by	the	theory	that	LSC	are	derived	from	more	mature	multi	or	unipotent	progenitor	cells	that	have	acquired	transforming	mutations,	providing	the	capacity	for	sustained	self-renewal.48	 LSCs	 are	 also	 thought	 to	 be	 biologically	 different	 to	 the	 AML	 blasts	 that	 they	produce.	LSCs	are	quiescent,	particularly	 in	the	G0	phase	of	the	cell	cycle	and	may	home	to	the	
bone	marrow	microenvironment,	avoiding	apoptosis	and	elimination	with	conventional	therapies	that	target	proliferating	cells.49		It	remains	a	cause	of	debate	as	to	whether	the	causative	mutations	and	subsequent	creation	of	the	LSC	develop	at	 the	 stage	of	multipotent	HSCs	or	more	mature	myeloid	progenitors.50	 	The	LSC	population	has	traditionally	been	thought	to	be	found	in	the	CD34+/CD38-	population.51,52	This	was	 based	 upon	 serial	 transplantation	 studies,	 performed	 using	 nonobese	 diabetic/severe	combined	 immunodeficiency	 (NOD/SCID)	mice,	which	 showed	 that	 only	 the	CD34+CD38-	 cells	were	capable	of	self-renewal.52	However,	several	xenotransplantation	studies	using	human	adult	AML	samples,	have	found	all	CD34/CD38	positive	and	negative	fractions	can	contain	functional	LSC	 that	 engraft,	 initiate	 and	 maintain	 the	 leukaemic	 process	 in	 immunodeficient	mice.9,42,44,49,50,53,54	It	is	important	to	note,	that	the	ability	of	the	leukaemic	cells	to	engraft	is	highly	dependent	on	the	immunodeficient	strain	of	the	mice	used.	For	example,	Taussig	et	al,	showed	that	CD34+CD38+	 cells	 contained	 leukaemia-initiating	 cells	 using	 immunodeficient	 NOD/SCID/β2-microglobulin	 null	 (NOD/SCID/β2m	 -/-),	 and	 NOD/SCID/IL2	 receptor	 γ	 chain	 null	(NOD/SCID/IL2rγ-/-)	 mice	 treated	 with	 human	 immunoglobulin	 or	 anti-CD122	 antibody	 to	increase	 immunosuppression.55	 Therefore,	 the	 mice	 used	 in	 this	 study	 were	 more	immunodeficient	than	the	NOD/SCID	mice	used	in	earlier	studies.			Goardon	 et	 al,	 provided	 evidence	 to	 show	 that	 the	 LSC	 in	 human	 adult	 AML	 can	 arise	 from	 a	CD34+CD38-	multipotent	progenitor	(lymphoid	primed	multipotential	progenitors	(LMPP)-like)	present	in	the	haematopoietic	hierarchy	below	the	level	of	the	HSC	and	MPP,	and	a	CD34+CD38+	unipotent	progenitor	population	(granulocyte-macrophage	progenitor	(GMP)-like).56	In	addition,	it	has	been	shown	that	25%	of	AMLs	are	CD34	negative	(defined	as	less	than	2%	CD34+	cells).48	Quek	 et	 al,	 report	 that	 CD34-	 LSCs	most	 closely	 resemble	 granulocyte-macrophage	 precursors	although	they	also	express	multiple	normal	HSC	transcriptional	regulators	associated	with	self-renewal.48	However,	there	are	some	AMLs	that	have	both	a	CD34+	compartment	(2-20%	of	total	blast	population)	and	CD34-	compartment	(up	to	98%)	that	are	not	classed	as	a	CD34-	AML.	Both	compartments	contain	functional	LSCs	and	illustrate	that	multiple	clones	can	be	present	within	individual	AMLs.48,56,57			Papemmanuil	et	al,	showed	that	86%	of	adult	patient	AMLs	had	2	or	more	driver	mutations	with	patterns	 of	 co-mutation.5	 They	 confirmed	 the	 hypothesis	 that	 initial	mutations	 develop	 in	 the	founding	clone	e.g.	DNMT3A,	TET2,	IDH1/2,	and	are	followed	by	later	transforming	mutations	e.g.	NPM1,	causing	overt	disease.5	It	has	also	been	shown	that	in	childhood	AML	specific	translocations	e.g.	t(8;21),	develop	prenatally	but	do	not	necessarily	result	in	overt	leukaemia	and	a	second	event	post-natally	is	most	likely	required	for	transformation	to	AML.58	Initial	mutations	or	translocations	generate	 quiescent	 pre-leukaemic	 stem	 cells	 with	 the	 potential	 to	 form	 a	 founding	 clone	 but	require	 further	driver	mutations	 to	develop	overt	AML.	 It	may	be	 the	 case,	 that	 the	 secondary	genetic	or	 epigenetic	mutations	are	 acquired	 in	 the	more	mature	progeny	of	 the	preleukaemic	stem	cells.50	(Figure	1)		
		
Figure	 1:	 Summary	 of	 generalised	 models	 describing	 multi-step	 process	 in	 AML	
development	from	cells	at	different	stages	of	maturity	The	green	circles	represent	normal	cells	within	in	the	fetal	liver	or	bone	marrow	in	utero	or	in	the	bone	 marrow	 after	 birth	 at	 different	 stages	 of	 maturity:	 haematopoietic	 stem	 cell	 (HSC),	multipotent	 progenitor	 (MPP),	 lymphoid	 primed	 multipotent	 progenitor	 (LMPP),	 committed	myeloid	 progenitor	 (CMP),	 granulocyte-macrophage	 progenitor	 (GMP)	 or	 granulocyte-macrophage	(GM)	precursor.	A	star	represents	one	or	more	insults	that	results	in	a	change	within	the	 cell	 or	microenvironment	e.g.	 translocation	or	genetic	or	 epigenetic	mutation.	An	 initiating	mutation	results	in	the	development	of	a	preleukaemic	stem	cell	(purple)	that	gains	self-renewal	capacity.	Further	transforming	mutations	occurs	leading	to	development	of	the	LSC	(CD34+	red,	CD34-	orange)	that	can	produce	the	bulk	AML	blasts	(CD34+	red	CD34-	orange).46,48,50,56	There	are	exceptions	 to	 the	proposed	models	 in	 this	 figure.	 For	 example,	MLL-fusion	 genes	 alone	 can	be	sufficient	to	cause	infantile	AML	without	a	second	genetic	hit.58		
CD33	expression	in	AML		CD33	is	a	member	of	the	sialic	acid	binding	immunoglobulin(Ig)	like	lectins	(Siglecs),	a	subset	of	the	immunoglobulin	superfamily	molecules.42,59	CD33	is	an	attractive	therapeutic	target	in	AML	due	to	the	frequent	expression	of	this	transmembrane	glycoprotein	on	adult	and	childhood	AML	blasts	and	importantly	identified	on	adult	LSCs.	Extracellularly,	CD33	has	two	Ig-like	domains:	V	set	 Ig	 like	 domain	 and	 C2	 set	 Ig-like	 domain.59,60	 Intracellularly,	 the	 cytoplasmic	 tail	 has	 one	immunoreceptor	tyrosine	based	inhibitory	motif	(ITIM)	and	a	second	ITIM-like	tyrosine	residue.	(Figure	 2).	 CD33	 has	 endocytic	 properties	 when	 bound	 by	 bivalent	 antibodies	 that	 result	 in	internalisation	of	the	antigen/antibody	complex.	Therefore,	binding	of	an	antibody	reduces	the	cell	surface	 expression	 of	 CD33	 but	 new	 CD33	 sites	 are	 continuously	 expressed.59,61	 Alternative	splicing	of	RNA	can	produce	CD33	transcript	variants	that	results	in	changes	in	the	structure	of	CD33,	for	example,	a	CD33	splice	variant	missing	exon	2	results	in	loss	of	the	V-set	domain.	This	is	important	clinically,	as	the	altered	CD33	may	no	longer	serve	as	a	target	for	anti-CD33	directed	therapy	 due	 to	 loss	 of	 epitopes.59,62	 Single-nucleotide	 polymorphisms	 (SNP)	 have	 also	 been	identified	in	paediatric	patients	and	may	be	associated	with	CD33	expression	levels	and	response	to	 GO	 treatment.63	 Intracellular	 mutations	 in	 the	 ITIMs	 have	 also	 been	 shown	 to	 impair	 the	endocytic	 properties	 of	 the	 receptor	 and	 subsequent	 internalisation	 of	 the	 antibody-CD33	complex.60	 The	 function	 of	 CD33	 in	 normal	 and	 AML	 cells	 remains	 largely	 unknown.	 There	 is	increasing	 evidence	 that	 it	 negatively	 regulates	 inflammatory	 and	 immune	 responses	 through	inhibitory	effects	on	tyrosine	kinase-driven	signalling	pathways.59		
	
	
Figure	2:	Structure	and	Signalling	Pathway	of	CD33		67kd	 single	 pass	 transmembrane	 glycoprotein	 containing	 an	 amino-terminal	 V	 set	Immunoglobulin-	like	domain	that	binds	sialic	acid	and	a	C2	set	Ig-like	domain	in	its	extracellular	
portion.	 The	 cytoplasmic	 tail	 contains	 a	 tyrosine-based	 inhibitory	 signalling	 motif	 (ITIM)	 at	position	340	and	an	ITIM-like	domain	at	position	358.	These	domains	are	phosphorylated	by	SRC	family	 kinases.59	 Once	 phosphorylated,	 they	 act	 as	 docking	 sites	 for	 SRC	 homology	 2	 domain	containing	proteins	e.g.	Src	Homology	2	containing	phosphatases	1	and	2	(SHP1	and	SHP2).	SH2	domain	containing	suppressor	of	cytokine	signalling	3	(SOCS3)	competes	with	SHP1	and	SHP2	for	binding	to	the	ITIM.50,59,64	SOCS3	has	a	SOCS	box	motif	that	allows	it	to	form	an	E3	ubiquitin	ligase	complex.	This	results	in	the	combined	effects	of	regulation	of	CD33	endocytosis,	reduced	myeloid	cell	 activation	 and	proliferation	 and	 increased	 receptor	 degradation.	 SOCS3	however	 has	 been	shown	to	reverse	the	CD33	induced	inhibition	of	cell	proliferation.64			CD33	is	normally	expressed	on	the	myeloid	lineage	at	the	early	stages	of	myeloid	differentiation,	being	found	on	normal	multipotent	and	unipotent	myeloid	progenitors,	myeloid	precursors	and	maturing	granulocytes	and	monocytes.59	The	general	consensus	from	the	current	literature,	based	on	 in	 vitro	 studies	 and	 multi-lineage	 engraftment	 of	 CD33-depleted	 autologous	 bone	 marrow	transplants	 in	 patients,	 is	 that	 CD33	 is	 not	 expressed	 on	 pluripotent	HSCs.42,43,45,59,65	 However,	there	is	a	growing	body	of	evidence	to	contradict	this.	Taussig	et	al,	showed	that	CD34+CD38-CD33+	healthy	 donor	 samples	 were	 capable	 of	 self-renewal	 by	 performing	 serial	 transplantation	 in	immunodeficient	mice,	 indicating	that	 this	 fraction	contains	HSCs.54	Krupta	et	al,	more	recently	showed	that	CD33	was	expressed	on	the	CD34+CD38-	population	of	bone	marrow	from	healthy	donors	but	at	a	significantly	lower	intensity	than	that	of	LSCs.19			CD33	is	expressed	on	blast	cells	in	85-90%	of	patients	presenting	with	AML	and	also	in	the	AML	LSC	 fraction	 but	 with	 significant	 heterogeneity	 in	 the	 level	 of	 expression	 and	 intensity.45,54,19	Studies	in	adults	analysing	CD33	expression	at	the	level	of	the	LSC	(CD34+CD38-	fraction),	showed	that	there	were	comparable	levels	of	CD33	expression	on	bulk	and	LSCs	in	the	majority,	but	not	in	all	 patients.43,45	 For	 example,	 if	 a	 patient	 highly	 expressed	 CD33	 on	 blasts	 (>60%),	 the	 LSCs	identified	 as	 CD34+CD38-CD123+	 cells	 co-expressed	 CD33.	 Conversely	 the	 LSC	 population	(CD34+CD38-CD123+	cells)	in	a	AML	with	CD33-	blasts,	were	shown	to	be	negative.43	However,	there	is	inter-patient	variation	and	the	level	of	expression	and	intensity	of	CD33	on	CD34+CD38-	cells	cannot	be	consistently	predicted	from	CD33	expression	on	the	‘bulk’	AML	blasts.			CD33	 expression	 has	 been	 shown	 to	 vary	 between	 morphological,	 cytogenetic	 and	 molecular	classifications	of	AML	(table	1).	FLT3-ITD,	NPM1	and	CEBPA	mutated	subgroups	are	consistently	associated	with	high	CD33	expression	in	both	adult	and	childhood	AML.	Complex	karyotypes	and	core	binding	factor	(CBF)	AML	(t(8;21)	and	inv(16))	are	associated	with	low	CD33	expression	in	the	 bulk	 AML	 population.66,45,19,18	 Khan	 et	 al,	 interestingly	 showed	 in	 adult	 patients	 that	 the	CD34+CD38-	fraction	in	core	binding	factor	AML	expressed	CD33	while	patients	with	intermediate	and	adverse	risk	disease,	the	CD34+CD38-	fraction	was	more	heterogeneous,	containing	significant	numbers	of	CD33	negative	cells.66	This	suggests	that	CBF	AML	may	have	differences	in	expression	patterns	of	CD33,	and	removal	of	CD33+	LSCs,	may	explain	the	favourable	clinical	response	seen	in	adult	patients	receiving	anti-CD33	therapy.			
	
Gemtuzumab	Ozogamicin	in	AML		Due	to	the	high	frequency	of	CD33	expression	on	AML	blasts	and	importantly	LSCs,	the	absence	or	lower	CD33	expression	on	normal	HSCs,	and	its	endocytic	properties,	CD33	has	been	of	interest	as	a	 therapeutic	 target.	 Gemtuzumab	 Ozogamicin	 (GO),	 an	 anti-CD33	 ADC,	 was	 the	 first	 targeted	treatment	 in	 AML	 to	 receive	 accelerated	 approval	 by	 the	 United	 States	 Food	 and	 Drug	Administration	 (FDA)	 in	 2000	 for	 adults	 greater	 than	 60	 years	 with	 relapsed	 AML.	 This	subsequently	was	voluntarily	withdrawn	in	2010	due	to	toxicity	concerns.	This	was	following	a	randomised	control	trial	(RCT)	performed	by	the	South	Western	Oncology	Group	(SWOG)	which	assigned	adult	patients	conventional	 first	 line	chemotherapy	with	or	without	GO	therapy.	They	found	no	clinical	improvement	but	an	increase	in	mortality	with	GO	therapy.	However,	this	RCT	used	different	anthracycline	doses	in	the	two	groups	which	may	have	negated	the	beneficial	effects	of	GO	and	the	mortality	rate	in	the	control	group	was	lower	than	that	normally	expected.	Meta-analysis	data	based	predominantly	on	adult	patients	however,	shows	benefit	from	GO	in	selected	patients,	 with	 core	 binding	 factor	 (CBF)	 AMLs	 showing	 the	 greatest	 benefit	 (overall	 survival	benefit	due	to	significant	reduction	in	relapse	rate).67,68	The	adult	ALFA-0701	randomised	control	
trial,	was	an	instrumental	study	altering	the	dosing	schedule	of	GO,	in	an	attempt	to	reduce	toxicity,	particularly	the	liver	toxicity	and	risk	of	veno-occlusive	disease	(VOD),	associated	with	GO.	They	gave	GO	in	a	fractionated	dosing	pattern,	at	a	lower	dose	of	3mg/m2	on	days	1,	4	and	7	of	induction	chemotherapy	and	on	day	1	of	consolidation	cycles.69	Previously,	GO	was	given	at	a	higher	single	dose	of	9mg/m2.	The	rationale	for	this	pattern	of	dosing	was	related	to	high	levels	of	saturation	of	CD33	 in	 vitro	at	 a	 dose	 of	 4mg/m2	 and	 the	 rapid	 re-expression	 of	 CD33	molecules	 on	 the	 cell	surface.69	The	estimated	2	year	event-free	survival	(40.8%	GO	vs	17.1%	control),	overall	survival	(53.2%	 GO	 vs	 41.9%	 control)	 and	 relapse	 free	 survival	 (50.3%	 GO	 vs	 22.7%	 control)	 were	significantly	 improved	 in	 the	GO	group.69	 Severe	 adverse	 events	 remained	higher	 in	 the	 group	receiving	GO,	mainly	due	to	persistent	thrombocytopenia	and	two	cases	of	VOD,	but	no	difference	in	induction	deaths	were	seen.	Consistent	with	other	RCTs,	the	benefit	was	most	pronounced	in	patients	with	 favourable	 cytogenetics	 i.e.	 CBF-AML.	 They	 also	 noted	 a	 pronounced	 benefit	 for	patients	with	FLT3-ITD	mutations	compared	to	negative	patients,	therefore	identifying	a	high-risk	group	of	patients	who	respond	to	GO.			The	Children’s	Oncology	Group	(COG)	have	also	shown	the	benefit	of	GO	in	children	with	CD33	AML.	 The	 RCT	 AAML0531	 compared	 paediatric	 patients	 being	 treated	 with	 conventional	chemotherapy	 alone	 or	 in	 combination	 with	 GO,	 and	 found	 GO	 recipients	 had	 significantly	improved	event	free	survival	at	3	years	(53.1%	GO	vs	46.9%	control)	as	well	as	relapse	risk	(32.8%	GO	vs	41.3%	control)	and	disease-free	survival	(60.6%	GO	vs	54.7%	control)	in	those	receiving	GO.1,18	Pollard	et	al,	 analysed	CD33	expression	and	clinical	 response	 to	GO	 therapy	 in	children.	They	found	that	patients	with	the	lowest	CD33	expression	(quartile	1)	who	received	GO	had	similar	outcomes	to	those	treated	with	conventional	chemotherapy	alone	(EFS	GO	53%	vs	58%	control,	RR	36%	GO	vs	34%	control).18	Surprisingly	45%	of	this	cohort	had	CBF	AML,	which	as	discussed	have	shown	greatest	response	to	GO.18	Patients	with	CD33	expression	within	the	higher	quartiles	(Q2-4)	had	higher	complete	remission	rates	for	those	who	received	GO	therapy.	High	risk	patients,	with	high	CD33	expression	treated	with	GO	had	a	reduced	relapse	rate	of	40+/-18%,	compared	to	73+/-22%	in	those	who	did	not	receive	GO.18	Therefore,	 in	children,	GO	lacks	clinical	benefit	 in	patients	 with	 lowest	 CD33	 expression	 but	 reduces	 relapse	 rate	 in	 those	 with	 higher	 CD33	expression,	 regardless	 of	 cytogenetic	 risk	 group.	 18	 Khan	 et	 al,	 reviewed	 CD33	 expression	 and	response	to	GO	in	adult	patients,	and	in	contrast	to	the	paediatric	patients,	CD33	expression	was	not	independently	prognostic	for	outcomes	to	GO.66	There	was	a	difference	in	the	percentage	of	CBF-AML	within	the	low	CD33	expression	group	(45%	of	CBFs	in	Q1	in	paediatric	cohort	vs	29%	of	CBFs	in	Q1	in	adult	cohort).66	This	shows	that	a	higher	proportion	of	children	with	CBF-AML	in	the	 COG	 cohort	 had	 low	 CD33	 expression	 compared	 to	 the	 adult	 cohort.	 The	 findings	 again	illustrate	that	childhood	and	adult	AML	have	different	genetic	profiles,	and	that	this	can	result	in	different	 responses	 to	 the	 same	 treatment.	 It	 emphasises	 the	 importance	 of	 investigating	 the	specific	 paediatric	 responses	 to	 treatments,	 rather	 than	 assuming	 results	 can	 be	 transferable	across	the	age	groups.			GO	has	had	a	turbulent	past	but	due	to	evidence	of	improved	outcomes	in	selected	patients	and	reassurance	regarding	toxicity,	GO	is	gaining	favour	and	is	currently	being	investigated	along	with	induction	 chemotherapy	 in	 a	 lower,	 fractionated	 dosing	 schedule	 in	 paediatric	(Myechild01/NCT02724163)	 and	 adult	 (NCRI	 AML18/ISRCTN31682779	 and	AML19/ISRCTN78449203)	AML	in	the	United	Kingdom.	The	above	trials	are	currently	recruiting	patients	and	will	close	in	November	2021,	June	2019	and	May	2020	respectively.			GO	 consists	 of	 a	 humanised	 murine	 IgG4	 anti-CD33	 antibody	 (clone	 hP67.6),	 linked	 via	 a	hydrolysable	 bifunctional	 linker	 to	 the	 N-acetyl-ƴ-calicheamicin	 dimethyl	 hydrazide	(CalichDMH).59–61,70	GO	binds	to	the	surface	CD33	and	the	complex	is	rapidly	internalised.	CD33	positivity	 is	 required	 in-vitro	 for	 GO-induced	 cytotoxicity,	 particularly	 at	 clinically	 achievable	plasma	levels.54,60,71	The	mean	peak	plasma	level	in	an	adult	patient	after	the	first	dose	of	9mg/m2	GO	is	3µg/ml.60	CD33	is	continuously	re-expressed	on	the	surface	of	the	cells	and	allows	further	uptake	of	GO.61	In	the	acidic	conditions	of	the	lysosome,	the	bifunctional	linker	is	hydrolysed	and	the	free	CalichDMH	is	reduced	to	a	diradical	species,	that	binds	to	the	minor	groove	of	DNA,	causing	single	and	double-strand	DNA	breaks	and	a	strong	DNA	damage	response,	with	phosphorylation	of	the	minor	histone	2A	variant	(H2AX)	and	increased	activation	of	DNA-dependent	protein	kinase	(DNA-PK).60,72	The	 IgG4	hP67.6	antibody	alone	 is	not	associated	with	cell	death	but	acts	as	 the	vehicle	for	drug	delivery.	Human	cells	exposed	to	GO	in	vitro,	undergo	cell	cycle	arrest	at	G2/M	
phase	 and	 cells	 either	 undergo	 apoptosis	 or	 can	 escape	 cell	 death	 through	 DNA	 repair.60,73	Apoptosis	is	thought	to	be	independent	of	p53	and	result	from	mitochondrial	induced	apoptosis.	Proapoptotic	proteins,	BAX	and	BAK1	are	thought	to	be	important	 in	sensitivity	to	GO,	through	formation	of	the	mitochondrial	permeability	transition,	release	of	cytochrome	C	and	activation	of	caspase	 3	 and	 9.74,61,70	Members	 of	 the	 ATP-binding	 cassette	 (ABC)	 superfamily	 of	 transporter	proteins,	P-glycoprotein	(Pgp/MDR1)	and	multi-drug	resistance	protein	1	(MRP-1)	are	thought	to	reduce	sensitivity	and	DNA	damage	by	efflux	of	CalichDMH	out	of	the	cell.72	Yamauchi	et	al,	created	GO-resistant	cell	lines	by	incubating	the	human	cell	line	HL-60	with	increasing	doses	of	GO	over	an	8	month	time	frame	followed	by	limited	dilution	cell	clone	selection.	They	saw	upregulation	of	DNA	repair	 proteins	 at	 the	 gene	 and	 protein	 level	 (XRCC5,	 PARP1,	 RPA,	 GADD45A)	 compared	 to	sensitive	cell	 lines	providing	support	 for	DNA	repair	pathways	 in	 resistance	 to	GO.72	They	also	provide	evidence	to	suggest	that	CD33	expression	levels,	drug	efflux	transporters	and	upregulation	of	DNA	repair	pathways	all	contribute	in	part	to	the	development	of	GO	resistance	(Figure	3).			
		
Figure	3:	Summary	of	GO	induced	cytotoxicity	and	influencing	factors.	GO	attaches	to	CD33	on	cell	surface	and	the	complex	is	internalised,	where	the	bifunctional	linker	is	hydrolysed	within	the	lysosome.	The	calicheamicin	ƴ1	derivative	enters	the	nucleus,	binds	to	DNA,	and	causes	single	and	double	strand	DNA	breaks.	Free	calicheamicin	is	pumped	from	the	cell	from	drug	transporters,	e.g.	P-glycoprotein.	CD33	is	continuously	re-expressed.	The	DNA	damage	results	 in	 cell	 cycle	 arrest,	 DNA	 repair	 pathways	 and	 mitochondrial	 induced	 apoptosis.	 Cells	entering	 cell	 cycle	 arrest	 can	 avoid	 apoptosis	 through	 upregulation	 of	 anti-apoptotic	 proteins	(Bcl2/BclXL)	 and	 DNA	 repair	 proteins	 (XRCC5,	 PARP1,	 RPA,	 GADD45A).	 MPT	 (mitochondrial	permeability	transition).		
	
Future	anti-CD33	therapies	and	treatment	combinations	
	Monoclonal	 anti-CD33	 antibodies	 have	 had	 less	 success	 clinically	 than	 their	 conjugated	counterparts.	 The	 original	 anti-CD33	 monoclonal	 antibody,	 lintuzumab	 showed	 good	 disease	response	in	pre-clinical	and	early	phase	trials	but	did	not	improve	survival	outcomes	in	patients.	A	new	Fc-engineered	CD33	antibody,	BI836858,	is	currently	being	tested	in	a	phase	I	trial	involving	
adults	with	 relapsed	 or	 refractory	AML	 and	 those	 at	 high	 risk	 of	 relapse	who	 are	 in	 complete	remission	(NCT01690624,	estimated	completion	March	2019).			Vadastuximab	 talirine	 (SGN-CD33A)	 is	 a	 novel	 ADC	 against	 CD33.	 It	 consists	 of	 an	 anti-CD33	engineered	cysteine	antibody	stably	linked	to	a	highly	potent	pyrrolobenzodiazepine	(PBD)	dimer.	The	ADC	is	 internalised,	transported	to	the	lysosome	where	the	linker	is	cleaved	by	proteolytic	enzymes	and	the	PBD	dimer	causes	DNA	damage	and	apoptosis	through	crosslinking	DNA.	It	was	shown	pre-clinically	to	be	effective	against	p53	mutated	and	multi-drug	resistant	AML.75	Interim	results	from	a	Phase	I	trial	have	shown	promising	results	with	marrow	blast	clearance	in	47%	of	adult	patients	with	either	relapsed	AML	or	who	declined	conventional	 intensive	chemotherapy,	receiving	 single	 agent	 vadastuximab.76	 A	 further	 phase	 1b	 study	 looking	 at	 vadastuximab	 in	combination	with	standard	induction	chemotherapy	showed	a	combined	complete	response	(CR)	and	complete	response	with	incomplete	blood	count	recovery(CRi)	rate	of	74%	with	no	significant	increase	 in	hepatotoxicity.77	Recently,	due	to	concerns	regarding	hepatotoxicity	and	VOD	in	the	bone	marrow	transplant	population,	the	FDA	have	placed	a	clinical	hold	or	partial	clinical	hold	on	three	vadastuximab	phase	I	trials.	The	CASCADE	trial	is	continuing	to	recruit.			A	 further	 ADC,	 IMGN779,	 is	 an	 anti-CD33	 antibody	 conjugated	 to	 DGN462,	 an	 indolino-benodiazepine	dimer	with	potent	DNA	alkylating	properties.	It	has	been	shown	to	have	in	vitro	and	in	vivo	activity,	particularly	against	FLT3-ITD	mutated	AML.78,79	This	ADC	is	being	trialled	in	a	phase	 I	 study	 in	 adult	 patients	 with	 relapsed/refractory	 CD33	 positive	 AML	 (NCT02674763,	estimated	completion	March	2019).		
	Bispecific	T	cell	engaging	(BiTE)	antibodies	are	novel	therapies	that	have	shown	success	in	other	leukaemias	e.g.	blinatumomab	in	Acute	Lymphoblastic	Leukaemia.	A	CD33/CD3	BiTE,	AMG	330,	engages	T	cells	with	its	CD3	binding	site	and	brings	the	T	cell	alongside	the	AML	blast	via	the	CD33	binding	site,	resulting	in	T	cell-induced	cell	death.	Pre-clinical	studies	have	shown	that	this	drug	is	effective	 against	 CD33	 expressing	 blasts,	 potentially	 avoiding	 the	 drug	 efflux	 drug	 resistance	methods,	 and	 does	 not	 reduce	 CD33	 expression	 through	 internalisation	 as	 seen	with	 bivalent	antibodies	e.g.	GO80.	Phase	I	clinical	trials	in	adults	are	now	underway	to	investigate	the	safety	and	efficacy	of	 this	drug	 in	patients	with	relapsed/refractory	AML	(NCT02520427,	estimated	study	completion	June	2018).			Chimeric	 antigen	 receptor	 targeting	 (CART)	of	CD33	 is	 another	 exciting	new	approach	 to	 anti-CD33	therapy.	This	approach	involves	engineering	T	lymphocytes	to	express	anti-CD33	chimeric	antigen	receptors,	often	with	co-stimulatory	 inflammatory	signals,	 resulting	 in	T	cell	activation	following	 contact	 with	 CD33	 and	 resultant	 blast	 cell	 death.	 Pre-clinical	 studies	 in	 adults	 and	paediatric	AML	human	samples	have	shown	excellent	cytotoxic	responses.81,82	There	are	phase	I	trials	underway	in	China	(NCT02799680,NCT02944162:	CAR-pNK	including	children	>3	years).	There	is	a	major	concern	regarding	the	potential	for	prolonged,	profound	myelosuppression	with	this	therapy	and	novel	strategies	to	prevent	this	will	be	required.82		The	 combination	 of	 hypomethylating	 agents	 and	 anti-CD33	 therapy,	 including	 GO,	 BI836858,	vadastuximab	and	AMG-330,	appears	to	be	advantageous	due	to	increased	CD33	expression	and	increased	sensitivity	to	DNA	damage	and	apoptosis	with	hypomethylating	agents	in	pre-clinical	trials.80,83–86	 The	 combination	 of	 hypomethylating	 agents,	 azacitidine	 and	 decitibine,	 with	vadastuximab	is	currently	being	assessed	clinically	in	a	randomised	control	trial	recruiting	older	adult	patients	with	newly	diagnosed	AML	(CASCADE/NCT02785900,	estimated	completion	date	September	2021).	
	
Summary		There	is	growing	evidence	that	the	pathogenesis	of	childhood	and	adult	AML	is	different,	and	that	they	can	respond	differently	 to	 treatment.	However,	 the	main	genetic	driver,	 regardless	of	age,	remains	an	important	indicator	of	response	to	treatment	and	prognosis.	CD33	is	a	promising	target	in	both	childhood	and	adult	AML,	as	it	is	expressed	on	a	variety	of	AML	subtypes	with	different	mutational	landscapes,	and	clinical	benefit	has	been	shown	with	Gemtuzumab	Ozogamicin	(GO).	This	benefit	is	only	seen	in	selected	groups	of	patients	and	it	is	important	to	identify	these	patients	to	avoid	unnecessary	toxicity.	The	level	of	CD33	expression	does	appear	to	have	a	role	in	response,	
particularly	in	children,	but	as	clinical	benefit	is	seen	in	cytogenetic	groups	with	low	CD33	levels,	other	 factors	 must	 have	 a	 role	 in	 sensitivity.	 Drug	 efflux	 transporters,	 CD33	 transmembrane	structural	variants,	LSC	response	and	upregulation	of	DNA	repair	pathways	may	all	contribute	to	the	 effectiveness	 of	 GO.	 To	 enable	 further	 understanding	 and	 guide	 development	 of	 new	generation	CD33-directed	drugs	or	drug	combinations,	further	investigation	into	the	response	of	the	LSC,	CD33	signalling	pathways	and	resistance	to	CD33	therapies	is	required.			
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Table	
Genetic	abnormalities	by	age 14-17
Incidence	in	Children	% Incidence	in	Adults	% CD33	Expression	Intensity 18-19 Immunophenotype Notes
Risk	group
Good	risk
t(8;21)(q22;q22);	RUNX1-RUNX1T1 14 7 CD33+	(weak) CD34+,	HLA-DR+,	MPO+,	CD13+,	CD15+/CD65+,	CD19+/-,	PAX5+/-,	CD79a+/-,	CD56+/- 20-23
inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11 7 5 CD33+(weak,	increased	heterogeneity	compared	to	t(8;21)2	populations:		1.	CD34+,	CD117+,	MPO ,	CD13+		2:	CD15+CD65+,	CD14+,	CD4+,	CD11b+,	CD11c+,	CD64+,	CD36+,	CD2+/- 23
t(15;17)(q22;q21)/PML-RARA 10 13 CD33+	(high)
CD34 low/absent ,	
HLA-DR 	low/absent ,	
CD117+/-,	CD13+,	
CD15-,	CD65-,	
CD64+,	CD11a-,	
CD11b-,	CD56+/- 23-
NPM1-mutated	AML	(normal	karyotype)	without	FLT3-ITD 5 33 CD33+	(high) CD34-,	HLA-DR-,	CD117+	(weak),	CD123+,CD13+,	MPO+,	CD64+CD14+,	CD11b+,	CD68+ 23,26
CEBPA	double	mutation	(normal	karyotype) 11 4 CD33+	(high,	heterogeneous) CD34+,	HLA-DR+,	CD13+,	CD65+,	CD11b+,	CD15+,	CD14-,	CD64-,	CD7+ 27
t(1;11)(q21;q23)/MLL-MLLT11 Rare Rare NA NA Not	good	risk	in	all	studies*
Intermediate	risk
t(9;11)(p22;q23)/MLL-MLLT3;t(11;19)(q23;p13.3)/MLL-
MLLT1;Other	MLL	rearrangements
11 5 CD33+	(high,	heterogeneous)
Children:	CD34-,	
HLA-DR+,	CD13-,	
CD14-,	CD65+,	
CD4+ 28
Adult:	CD34+/-,	
CD117+/-CD14+,	
CD4+,	CD11b+,	
CD11c+,	CD64+,	
t(1;22)(p13;q13)/ RBM15-MKL1 Rare <0.5 CD33+CD41a+,	CD42b+,	CD61+,	HLA-DR+/-,	CD34+/-,	CD45+/-30-31Usually	restricted	to	infants
DNMT3A	mutations 0 15 CD33+
CD34+/-,	CD11c+,	
CD14+,	MPO+,	
CD13+,	
AML DNMT3A/FLT3/
NPM1 :	
CD34+,	CD13+,	
CD123+,	CD3-,	
MPO+,	 associated	with	NPM1	mutations
IDH1/2	mutations 0 16 CD33+ CD117+,	HLA-DR+/-,	CD34+/-,	CD38+,	CD13+,	MPO+/-,	CD64+(FAB	M5	only) 35
Cytogenetic	abnormalities	not	classified	as	favorable	or	adverse 25 35 NA NA
Poor	risk
Monosomy	7 4 5 NA NA
Monosomy	5/deletion	of	chromosme	5	long	arm	(del(5q) ~2 ~5 NA NA
inv(3)(q21q26.2)	or	t(3;3)(q21;q26.2)/RPN1-MECOM(EVI1-MDS1-EAP) ~2 ~1 CD33+ CD13+,	CD33+,	CD117+,	MPO+/-,	HLA-DR+,	CD34+,	CD56+/-,	CD7+/-36
t(6;9)(p23;q34)/DEK-NUP214 ~2 ~1 CD33+CD9+,	CD13+,	CD38+,	CD117+,	CD15+/-,	HLA-DR+/-,	CD34+/-,	TdT+/- 37-38
t(7;12)(q36;p13)/ETV6(TEL)-HLXB9(MNX1) <1 0 NA NA restricted	to	infants
t(4;11)(q21;q23)/MLL-MLLT2(AF4);t(6;11)(q27;q23)/MLL-
MLLT4(AF6);t(10;11)(p12;q23)/MLL-MLLT10(AF10) 5 2 NA NA
t(11;12)(p15;p13)/NUP98-KDM5A ~1 0 NA NA
t(5;11)(q35;p15.5)/NUP98-NSD1 ~5 ~2 NA NA mostly	adolescents
inv(16)(p13.3q24.3)/CBFA2T3-GLIS2 <2 0 NA NA
t(9;22)(q34;q11.2)/BCR-ABL1 ~1 ~1 CD33+ CD34+,	CD13+,	CD19+/- 39
abnormal	chromosome	17	short	arm 3 ~2 NA NA
abnormal	chromosome	12	short	arm ~4 ~3 NA NA
in	adults,	always	seen	in	
complex	karyotype
WT1	mutation 8 9 NA NA
FLT3-ITD	in	absence	of	favourable	cytogenetic/genetic	features 10 25 CD33+	(high,	heterogeneous) CD34+/-,	HLA-DR+,	MPO+,	CD36+,	CD25+,	CD123+,	CD64+	CD99+,	CD117	+/-,	CD7+/-,	CD11b+/-,	CD4+/- 40-41
Complex	karyotype 13**** 9*** CD33+	(weak,	heterogeneous) Variable Not	poor	risk	in	children**
*	Good	risk	in	Balgobind	et	al,	not	confirmed	in	Harrison	et	al	2010
**	Harrison	et	al	2010
***based	on	four	or	more	abnormalities
NA-	not	available
